Featured Story | | | Tuesday, August 15, 2017 Spyridon "Spyros" Papapetropoulos has joined the ranks of small, neurological disease-focused biotech Cavion as EVP of research and development and CMO. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
90+ executive-level speakers share advanced partnership and pipeline strategies September 25-27 in Boston, MA. Learn to adapt to increased deal complexity, real world evidence, and digital technologies. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Tuesday, August 15, 2017 Lexicon Pharmaceuticals has bolstered the case for its Sanofi-partnered diabetes pill. The latest update means Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor sotagliflozin on A1C in patients with Type 1 diabetes is sustained over 52 weeks. Tuesday, August 15, 2017 A group of cancer patients with the ROS1 mutation has teamed up with a nonprofit and a precision medicine company to create disease models. The collaboration aims to drive forward research into treatments for the rare ROS1 gene mutation by gathering tissue samples from patients. Monday, August 7, 2017 Natural killer (NK) cells first earned their title as “killers” nearly 40 years ago when researchers observed the rapid immune response of these lymphocytes as they destroyed host cells infected with a virus or tumor cells. It seemed that NK cells could attach spontaneously without prior activation. Over time, researchers have learned more about the molecular mechanisms that regulate their activation and function. Tuesday, August 15, 2017 Shares in Cerecor leaped after the biotech licensed an antidepressant candidate to Johnson & Johnson, bringing in additional cash to advance its pipeline. The cash injection gives the Baltimore-based biotech operating cash through at least 2018. Tuesday, August 15, 2017 Following drug discovery collaborations with big pharma companies Merck & Co., Johnson & Johnson and Pfizer, DNA-encoded library technology expert HitGen just inked another multiyear, multitarget deal with Aduro Biotech. Tuesday, August 15, 2017 | By Merck CEO Ken Frazier made waves far beyond the pharma industry when he stepped down from President Donald Trump’s manufacturing panel Monday, taking a stand against “intolerance and extremism.” Where does that leave other drug executives who’ve worked with the president to push their proposals? Tuesday, August 15, 2017 | By GlaxoSmithKline opened its new $56.6 million vaccines plant in Montrose, Scotland, that will manufacture sterile aluminum salts and includes a microbiology lab. But the small addition comes as a much bigger project has been canceled. Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 15th Annual Discovery on Target September 25-29, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
